Vipadenant
- Generic Name
- Vipadenant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15N7O
- CAS Number
- 442908-10-3
- Unique Ingredient Identifier
- LDR3USH1NJ
- Indication
Investigated for use/treatment in parkinson's disease.
BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 28
- Registration Number
- NCT01017666
- Locations
- 🇬🇧
InCROM Clinical Research Unit, London, United Kingdom
Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT00531193
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT00442780
- Locations
- 🇷🇸
Research Sites, Belgrade, Serbia
🇷🇸Research Site, Belgrade, Serbia
Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2009-07-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 83
- Registration Number
- NCT00438607
- Locations
- 🇮🇳
Research Sites, Bangalore, India
🇬🇧Research Site, Salford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath